Management of Patients with Alzheimer’s Disease plus Cerebrovascular Disease: 12-Month Treatment with Galantamine

Publisher： Karger

E-ISSN： 1421-9824|17|1-2|29-34

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.17, Iss.1-2, 2003-12, pp. : 29-34

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Galantamine: Additional Benefits to Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 11, Iss. 1, 2000-09 ,pp. : 19-27

Karger

Access to resources Recommend Favorite

Galantamine Provides Sustained Benefits in Patients with ‘Advanced Moderate’ Alzheimer’s Disease for at Least 12 Months

By  

Dementia and Geriatric Cognitive Disorders, Vol. 15, Iss. 2, 2003-01 ,pp. : 79-87

Karger

Access to resources Recommend Favorite

Economic Analysis of Galantamine, a Cholinesterase Inhibitor, in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease in The Netherlands

By  

Dementia and Geriatric Cognitive Disorders, Vol. 14, Iss. 2, 2002-07 ,pp. : 84-89

Karger

Access to resources Recommend Favorite

Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 20, Iss. 2-3, 2005-08 ,pp. : 120-132

Karger

Access to resources Recommend Favorite

Galantamine for Alzheimer’s Disease and Mild Cognitive Impairment

By  

Neuroepidemiology, Vol. 28, Iss. 2, 2007-04 ,pp. : 116-117

Karger

Access to resources Recommend Favorite